Policlinico S. Orsola - Malpighi - UOC Nefrologia, Dialisi e Ipertensione
Bologna, Emilia-Romagna, 40138, Italy
Location status: Recruiting
Location contact
Annalisa Zucchelli, Prof.
CONTACT
Annalisa Zucchelli, Prof.
PRINCIPAL_INVESTIGATOR
NCT Number: NCT06376968
The goal of this prospective, randomized, controlled, cross-over, multicentric study is to demonstrate the safety of bioLogic Fusion in patients on chronic haemodialysis or hemodiafiltration prone to hypotensive episodes. The main question it aims to answer is:
• Which is the number and percentage of individual sessions with reached prescribed post-dialysis body weight in the prescribed treatment time in each single session in hypotensive-prone patients on high-flux haemodialysis or hemodiafiltration within each patient with treatments performed with DialogiQ with (treatment A) or without (treatment B) the bioLogic Fusion option activated? Participants will in addition to their routine dialysis treatment undergo 2 physical examinations and regularly answer questionnaires.
A crossover design is used to compare treatments with or without the BioLogic Fusion function activated.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Bologna, Emilia-Romagna, 40138, Italy
Location status: Recruiting
Annalisa Zucchelli, Prof.
CONTACT
Annalisa Zucchelli, Prof.
PRINCIPAL_INVESTIGATOR
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Dialysis conducted with Dialog iQ dialysis machine either using the BioLogic Fusion option or not using it. This is only a biologic feedback system using blood pressure and residual blood volume as parameters to predict potential hypotensive episodes. If switched off, standard dialysis treatment happens, if switched on, the system tries to predict and prevent hypotensive episodes.
Time frame: 12 weeks
percentage of sessions with reached prescribed post-dialysis body weight
Contact information is provided by the study sponsor or research team.
Seebode Christina, Dr.
CONTACT
Strube Frank
CONTACT
B.Braun Avitum AG
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06568835
Atrophy, Behavior
Chongqing, Chongqing Municipality, China
View Trial DetailsNCT07716436
Behavior, Chronic Disease
Tanta, Gharbia Governorate, Egypt
View Trial DetailsNCT07365111
Acute Kidney Injury, Continuous Renal Replacement Therapy (CRRT)
Edmonton, Alberta, Canada
View Trial DetailsNCT06584734
Aerobic Training, Diastolic Dysfunction
Mexico City, Mexico
View Trial Details